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hospital mortality, length of stay, resource use and the TISS 28,
a tool developed to assess workload of hospital staff for inten-
sive care patients. Economic aspects were assessed using pub-
lished average daily costs as approximation of item costs.
RESULTS: A total of 62% of ARDS patients were male, median
age of 55 years, and most patients with socioeconomic data were
either working or in retirement. The main predisposing events
for ARDS were sepsis (51%), pneumonia (35%) and trauma or
surgery (28%). During the initial hospitalization 70 patients
(36%) died. Overall length of hospital stay was 31 ± 41 (mean
± SD) days, with most days spent in the Intensive Care Unit (ICU;
20 ± 21 days) and General Ward (8 ± 22 days). On average
patients were artiﬁcially ventilated for 16 ± 14 days and intu-
bated for 16 ± 15 days. As assessed by the TISS 28, the average
daily TISS score was 33 ± 10, which corresponds to a nursing
time of 5.9 hours per day, and mainly related to basic activities
(12 ± 3), ventilatory support (6 ± 2) and cardio-vascular support
(10 ± 5). Average overall hospital costs amount to 38,263 USD
per patient. CONCLUSIONS: ARDS is a severe condition with
a high mortality during inpatient treatment. Patients are treated
mainly in the ICU requiring intensive artiﬁcial ventilation and
high nursing workload, thereby resulting in high treatment cost.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
is a debilitating disease. The purpose of this study was to char-
acterise the association between various clinical and quality of
life outcome parameters typically used to characterise respira-
tory illnesses, and utility, as measured by the EQ5Dindex.
METHODS: Data were abstracted from the Health Outcomes
Data Repository (HODaR), an ongoing survey of patients in a
UK region that included the EQ5D and the SF36 and the St.
George’s Respiratory Questionnaire (StGRQ). Detailed lung
function data (LFD) were also available on the same patients for
the 12-year period. Generalised linear models were used to esti-
mate utility from predictor variables and goodness of ﬁt was
ascertained by the proportion of predictions lying within 0.03
utility units. RESULTS: Complete data were available on 444
subjects. A multinomial regression model mapped the clinical
data from 315 (71%) of these subjects to EQ5Dindex and the
resulting model was then applied to an independent set of 
129 (29%) subjects. In the 315 subjects, 40%, 41% and 52%
of predictions were within 0.03 units when using i) the SF36
alone, ii) the SF36 with LFD and iii) the SF36 with LFD and St.
George’s data, respectively. The same models applied to the test
data set resulted in 33%, 33% and 29% of predictions within
0.03 units, respectively. For subjects with moderate to severe
COPD (based on the GOLD classiﬁcation) 49%, 53% and 79%
of predictions were within 0.03 units, respectively. The corre-
sponding ﬁgures for none or mild COPD (GOLD classiﬁcation)
were 47%, 49% and 86%, respectively. CONCLUSIONS: It was
possible to reliably model the EQ5Dindex from the SF36 in respi-
ratory disease; however, models that included the lung function
data provided a marginal improvement, and the availability of
the StGRQ conferred further improvement within the construc-
tion data set.
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OBJECTIVES: Analize the correlation among different ques-
tionnaires of quality of life and FEV1 in patients with COPD.
METHODS: Cross-sectional study of 126 patients with COPD
controlled in a primary care setting. Non-random sample.
Patients were asked to ﬁll in ﬁve questionnaires of quality of life
(Euroquol, Coop-Wonca vignettes -CW-, Nottingham Health
Proﬁle -NHP-, Saint George Respiratory Questionnaire -SGRQ-
and de Basal Dyspnoea Index -BDI-) and they also performed a
forced spirometry. Other variables measured were: age, sex,
study level, marital status, comorbidity, and prescribed treat-
ment. RESULTS: A total of 88.9% males, age (mean + std) 68.5
+ 8.5 years, 32% illiterates, 87% married; 70% received bron-
chodilator treatment; 74% had at least another comorbid con-
dition; FEV 1 57.2% + 19.5%. Quality of life was moderately
affected: Euroquol visual scale (6.2 + 2.1), C-W physical activ-
ity (3.6 + 0.9), C-W feelings (2.1 + 1.1), C-W daily activities (2.2
+ 0.1), C-W social activities (1.8 + 1.3), C-W change in health
status (2.5 + 0.8), C-W health status (3.5 + 0.9), C-W pain (2.5
+ 1.3), C-W social support (2.0 + 1.0), C-W quality of life (2.4
+ 0.7), NHP total (31.5.2 + 22.8), SGRQ (36.4 + 21.6), BDI-
functional impairment (2.9 + 0.9), BDI-magnitude of work (2.9
+ 0.9), BDI-magnitude of effort (2.9 + 0.9). Spearman correla-
tion coefﬁcient was statistically signiﬁcant among all the QOL
questionnaires excepted between Euroqol and BDI-magnitude of
work. This correlation was mild-moderate (r < 0.5). FEV1 cor-
related with BDI, SGRQ, C-W physical activity, C-W daily activ-
ities, C-W health status (r = 0.41; r = 0.38, r = -0.19, r = -0.27,
r = -0–21, respectively). Correlation was moderate-high among
BDI, NHP, SGRQ, and COOP-Wonca Vignetes (r > 0.5). CON-
CLUSIONS: Quality of life in patients with COPD is slightly cor-
related with functional status (specially speciﬁc respiratory
questionnaires and several vignettes of COOP-WONCA ques-
tionnaire). There is a good correlation between generic and spe-
ciﬁc QOL questionnaires in patients with COPD.
PRS18
DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED
BY THE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD
SEVERITY STAGES?
Rutten-van Molken MP1, Oostenbrink JB1, Monz BU2
1Erasmus MC, Rotterdam,The Netherlands; 2Boehringer Ingelheim
International, Ingelheim, Germany
OBJECTIVE: To assess the discriminative properties of the EQ-
5D with respect to COPD severity according to GOLD in a large
multinational study. METHODS: Baseline EQ-5D Visual Ana-
logue Scale (VAS) scores, EQ-5D utilities and SGRQ scores were
obtained from a subset of patients in the UPLIFT trial, a 4-yr
placebo-controlled trial of tiotropium in COPD patients aged ≥
40, FEV1% pred < 70, FEV1/FVC £ 70% and ≥10 pack years
of smoking to assess the rate of decline in FEV1. RESULTS:
1,235 patients (mean post bronchodilator FEV1% pred 48.77)
from 13 countries completed the EQ-5D. EQ-5D VAS and utility
scores differed signiﬁcantly between GOLD stages 2, 3 and 4,
also after correction for age, sex, smoking, BMI and co-
morbidity (p < 0.001). Mean (SD) EQ-5D VAS scores in GOLD
stages 2, 3 and 4 were 68 (16), 62 (17) and 58 (16), respectively.
Mean (SD) utilities were 0.79 (0.20) in GOLD 2, 0.75 (0.21) in
GOLD 3 and 0.65 (0.23) in GOLD 4. Effect sizes for the dif-
ference in utilities between GOLD 3 and 4 were more than twice
as high as for the difference between 2 and 3. Gender, post-
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bronchodilator FEV1% pred, number of hospital admissions and
ER visits in the year prior to baseline, number of concomitant
diagnoses and BMI were independently associated with EQ-5D
utility. Danish, Spanish and Dutch patients had signiﬁcantly
higher utilities than US patients. French patients had lower util-
ities. Utilities calculated with the US value set were on average
5% higher than utilities calculated with the UK set. CONCLU-
SIONS: Increasing severity of COPD was associated with signif-
icant decline of EQ-5D VAS scores and utilities. These results
demonstrate that a generic instrument can assess COPD impact
on quality of life and that the scores discriminate between
patients groups of known severity. These utilities will be useful
in cost-effectiveness assessments.
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OBJECTIVE: To develop and validate a self-reported question-
naire measuring the severity of dyspnoea and its impact on daily
life. METHODS: A list of daily life activities was selected by the
Scientiﬁc Committee (SC) after an extensive literature review.
This selection was tested during ﬁve interviews with respiratory
physicians, resulting in a modiﬁed list and a preliminary grading
system assessing how dyspnoea impacts on activities. After in-
depth interviews conducted with ten mild-to-severe COPD
patients, a test questionnaire was developed. Six new patients
completed the test questionnaire and commented its contents and
format. Two response choice formats (multiple or exclusive
response) were tested to describe the impact of dyspnoea on
activities. In addition, four new clinicians completed a standard
form evaluating the questionnaire after having used it in clinical
practice with four of their patients. The questionnaire was
revised according to all comments received. RESULTS: Five con-
cepts (self-care, physiological activities, activities at home, activ-
ities outside, and sport) and 48 activities were ﬁrst identiﬁed.
After clinician and patient interviews, some activities were
grouped, split, suppressed or added. The test questionnaire had
20 items. The recall period was set to a week. The descriptive
criteria of the impact of dyspnoea on activities were: abandoned,
slowed, need for pause, need for help, activities modiﬁed,
avoided. After the cognitive debrieﬁng and comments from both
patients and clinicians, the ﬁnal format was established as a mix
of the two tested formats. CONCLUSION: This pilot question-
naire assessing the impact of dyspnoea on COPD patients activ-
ities in real life was well accepted by both patients and doctors.
Further validation is needed to support its use and guide inter-
pretation in clinical practice and clinical trials.
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BACKGROUND: Cough and sputum are leading symptoms of
chronic (obstructive) bronchitis. It is acknowledged that these
symptoms impact patients’ lives, yet they have never been mea-
sured adequately. OBJECTIVE: To develop a self-administered
instrument in ﬁve countries (seven languages) that captures con-
cepts relevant to chronic (obstructive) bronchitis patients who
suffer from cough and sputum. METHODS: After literature
review and appraisal of existing instruments, a conceptual model
was developed and then reviewed by clinical respiratory experts.
Thirty extensive face-to-face concept elicitation interviews were
conducted with patients in ﬁve countries (France, Germany,
Japan, Spain, US). After transcription and domain-mapping of
the interviews in each country, an international item generation
meeting was conducted and a draft questionnaire was simulta-
neously created in ﬁve languages. After clinical expert review,
testing for face and content validity was performed in cognitive
debrieﬁngs in seven languages in six countries with 35 patients
(English for US/UK, French, German, Japanese, and Spanish for
US/Spain). RESULTS: The conceptual model addressed symp-
toms of cough and sputum and their respective impact. The
resulting questionnaire, Cough and Sputum Assessment Ques-
tionnaire (CASA-Q), has 25 items with 6 items for symptoms (3
cough, 3 sputum) and 19 items for the impact of these symp-
toms (12 cough, 7 sputum). The response choices per item
consist of ﬁve options from “never” to “always” or “not at all”
to “extremely”, depending on the context of the item. Due to its
simultaneous item generation in ﬁve languages and ﬁeld testing
in seven languages, item wording overall is following a simple
sentence structure. The ease of understanding and relevance of
each question was found acceptable across languages. CON-
CLUSION: The CASA-Q is a well-developed, patient-based
questionnaire relevant to the assessment of chronic bronchitis.
The CASA-Q, after completion of psychometric validation, may
contribute to a comprehensive patient-centered assessment.
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OBJECTIVES: Analize the patient satisfaction with COPD treat-
ment, and relation with different drugs. METHODS: Cross-
sectional study of 377 patients with COPD controlled in three
primary care settings. Non-random sample: patients were cited
in the health centers and were asked to answer 10 questions
about satisfaction with their treatment (positive scale 1–7). In
this interview the investigators carried out a spirometry. Other
variables measured were: age, sex, comorbidity, and prescribed
treatment. RESULTS: 331 (87.8%) males, age (mean + std) 67.7
+ 8.6 years, 53% had at least another comorbid condition; FEV
1 58% + 21%. In 63 patients (15%) we couldn’t ﬁnd any pre-
scribed treatment. 65% remaining received treatment with:
ß2agonist (55%), anticholinergic (30.8%), inhaled corticos-
teroids (35.5%), oral xantins (19.9%), oral corticosteroids
(7.3%) mucolitics (21.7%) oxygen therapy (4.1%). Only 6.2%
referred an adverse event with treatment. Patient satisfaction
with treatment: 62% satisﬁed because low adverse events; 61%
satisﬁed with drugs; 59.9% satisﬁed about daily life; 58.2%
showed satisfaction with effects onset; 61.4% satisﬁed with sleep
proﬁle; 59.1% showed satisfaction with symptoms control;
60.2% satisﬁed with time of doses. 44% preferred to take med-
ications once a day, 39.8% thought it’s important number of
time they had to take the drugs; 49.6% considered that the times
to take medication in a day doesn’t make it more complicated.
Males feel better symptoms control than females. Satisfaction
was higher in ß2 agonist (less adverse events, less importance on
times of dosage), anticholinergic drug (less adverse events, less
importance on times of dosage) and inhaled corticosteroids (less
